Comparative activity of the potent selective CDK2 inhibitor NU6102 in CDK2 wild-type and knock-out mouse embryo fibroblasts

作者
Yuzhu Cheng,Lan-Zhan Wang,Nicola J. Curtin,David R. Newell
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:65: 1043-1044
摘要

4409 Cyclin-dependent kinases (CDK) regulate cell cycle progression, and CDK deregulation due to cyclin over-expression, mutation or tumor suppressor gene malfunction is a common feature of human cancer. CDKs are being actively investigated as targets for cancer therapy, and CDK inhibitors have entered clinical trials, e.g. flavopiridol, R-roscovitine and BMS387032. CDK2, in association with cyclins E and A, is involved in G1/S and S phase progression, and molecular pathology studies have implicated CDK2 as a target for drug therapy. However, recent molecular genetic studies in tumor cell lines and in knock-out mouse models have questioned the validity of CDK2 as a target (Tetsu and McCormick Cancer Cell 2003 3:233; Ortega et al., Nature Genetics 2003 35:25). Specifically, mice with homozygous deletion of CDK2 grow normally and give rise to embryonic fibroblasts (MEFs) with equivalent replicative capacity to their WT counterparts. We have recently described the design and synthesis of NU6102 (6-cyclohexylmethoxy-2-(4’-sulfamoylanilino) purine), a potent and selective CDK2 inhibitor (Davies at al., Nature Structural Biology 2002, 9:745). The current study describes the growth inhibitory activity of NU6102 in CDK2 WT and KO MEFs in comparison to the standard compound R-roscovitine. The CDK inhibitory activities of NU6102 and R-roscovitine were defined using a panel of purified human CDKs, ATP concentrations of 12.5 microM (CDK1,2 and 4) or 100 microM (CDK5 and 7), and appropriate substrates. Concentrations (microM) required to inhibit CDKs (CDK1/B; CDK2/A3; CDK4/D; CDK5/p25; CDK7/H) by 50% were: 0.25+/−0.05; 0.005+/−0.001; 1.5+/−0.7; 0.48+/−0.07; 4.4+/−0.8 to NU6102; However, R-roscovitine against these CDKs were 6; 0.41+/−0.05; 5.5+/−1.1; 0.87+/−0.14; 0.84+/−0.04, respectively. Thus NU6102 shows 50-fold selectivity for CDK2, whereas R-roscovitine is less selective. In a 5-day sulphorhodamine B growth inhibition assay, NU6102 had a GI50 value of 9+/−2 microM for CDK2 WT MEFs, whereas there was no growth inhibition up to and including 25 microM in the CDK KO MEFs. At concentrations where NU6102 showed differential activity against the CDK2 WT MEFs (

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
Jyu的应助被Aurora采纳,获得10
刚刚
httpyg完成签到,获得积分10
1秒前
stan完成签到,获得积分20
1秒前
1秒前
2秒前
内向秋寒完成签到,获得积分10
2秒前
科研劝退完成签到,获得积分10
3秒前
3秒前
017发布了新的文献求助10
3秒前
3秒前
3秒前
lala完成签到,获得积分10
3秒前
3秒前
哈哈哈啊完成签到,获得积分10
3秒前
moooj发布了新的文献求助10
3秒前
Wendy完成签到,获得积分10
3秒前
脑洞疼的应助被梨花诗采纳,获得10
4秒前
实验室发布了新的文献求助10
4秒前
4秒前
科研通AI6.2的应助被kakavia采纳,获得10
4秒前
卢卡雷欢发布了新的文献求助10
4秒前
科研通AI6.2的应助被huanxian1995采纳,获得30
4秒前
大反应釜完成签到,获得积分10
5秒前
Joy发布了新的文献求助10
5秒前
棕棕完成签到,获得积分20
5秒前
mm发布了新的文献求助10
5秒前
5秒前
你家吗完成签到,获得积分10
5秒前
6秒前
曼粒子完成签到,获得积分10
6秒前
FFFF发布了新的文献求助30
6秒前
黑猫黑猫发布了新的文献求助10
6秒前
whyritoday发布了新的文献求助10
6秒前
SciGPT的应助被shan采纳,获得10
6秒前
硅烷聚合发布了新的文献求助10
6秒前
6秒前
will完成签到,获得积分10
7秒前
lala发布了新的文献求助30
7秒前
雷凯洲完成签到,获得积分20
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8161857
求助须知:如何正确求助?哪些是违规求助? 9556272
关于积分的说明 21733778
捐赠科研通 7751772
什么是DOI,文献DOI怎么找? 3427616
关于科研通互助平台的介绍 2552632
邀请新用户注册赠送积分活动 2472079